Publications by authors named "G Subaiea"
Background/objectives: The blood-brain barrier (BBB) significantly limits the treatment of central nervous system disorders, such as schizophrenia, by restricting drug delivery to the brain. This study explores the potential of intranasal clozapine-loaded lipid nanocapsules (IN LNCs) as a targeted and effective delivery system to the brain.
Methods: LNCs were prepared using the phase inversion technique and characterized in terms of size, zeta potential, entrapment efficiency (EE%), and in vitro drug release.
Non-coding RNAs (ncRNAs) have been recognized as pivotal regulators of transcriptional and post-transcriptional gene modulation, exerting a profound influence on a diverse array of biological and pathological cascades, including the intricate mechanisms underlying tumorigenesis and the acquisition of drug resistance in neoplastic cells. Glioblastoma (GBM), recognized as the foremost and most aggressive neoplasm originating in the brain, is distinguished by its formidable resistance to the cytotoxic effects of chemotherapeutic agents and ionizing radiation. Recent years have witnessed an escalating interest in comprehending the involvement of ncRNAs, particularly lncRNAs, in GBM chemoresistance.
View Article and Find Full Text PDFAmong the various types of cancer, lung cancer accounts for the highest number of fatalities across the globe. A combination of different cancer chemotherapeutics is regarded as an effective strategy for clinical management of different cancers. Ganetespib (GAN) is a well-established hsp90 inhibitor with enhanced pharmacological properties in comparison with its first-generation counterparts.
View Article and Find Full Text PDFFabrication and Characterization of Paclitaxel and Resveratrol Loaded Soluplus Polymeric Nanoparticles for Improved BBB Penetration for Glioma Management.
Polymers (Basel)
September 2021
Article Synopsis
- Gliomas are challenging brain tumors with limited treatment options, and this study investigates a new combination therapy using paclitaxel (PAX) and resveratrol (RESV) delivered via polymeric nanoparticles (PNPs).
- The PAX-RESV-loaded PNPs showed effective drug encapsulation and optimal characteristics, and in lab tests, they demonstrated stronger cancer-fighting effects on glioma cells compared to using the drugs separately.
- In animal studies, the nanoparticles significantly improved the absorption and brain delivery of the drugs, suggesting that this combination therapy could be a promising strategy for treating gliomas.
Article Synopsis
- Brain tumors account for about 3% of cancer-related deaths, with a focus on their prevalence and treatment options in Saudi Arabia, including the role of nanotechnology.
- A literature review highlighted that gliomas, astrocytomas, meningiomas, and metastatic cancers have higher incidence rates in Saudi Arabia and are primarily treated with conventional methods, which often lead to a poor prognosis.
- Nanomaterials, particularly polymer-based formulations, show promise in enhancing brain cancer treatment outcomes and reducing toxicity to normal cells, but further clinical studies are needed to establish their safety and efficacy.